TrialClinical cancer research : an official journal of the American Association for Cancer Research2010

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

Christina M Annunziata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.